Health & Biotech
Imricor is the global leader in the development and manufacture of MRI compatible devices for performing cardiac ablations. A cardiac ablation is a procedure conducted by an electrophysiologist where a catheter is guided into the heart with the purpose of burning/ablating the tissue responsible for causing the arrythmia (irregular heartbeat).
The cardiac ablation market, which is over US$8bn per year, currently uses X-Ray guidance to identify the location in the heart that requires treatment. X-Ray as an imaging tool has limitations as it does not show the soft tissue of the heart and exposes the patients and physicians to repeated radiation.
Imricor has the only cardiac ablation devices in the world that have been proven to be safe and effective inside the magnetic field generated by an MRI and, after 18 years of research and development, is now commercialising globally with approvals in Europe, the Middle East and soon to be in both Australia (2024) and the US (2025). The technology is protected by over 70 global patents.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Scott Power: Which small medtech lifted 70pc this week after US contract win?
Health & Biotech
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
Health & Biotech
Scott Power: Which ASX healthcare stock has soared 30pc this week?
News
ASX Lunch Wrap: It’s a bumpy start to Friday, but tech sector finds upside
News
ASX Lunch Wrap: ASX closes on record high and BTC surges despite Wall Street lead
Health & Biotech
Imricor performs first atrial flutter ablation at Swiss hospital
Health & Biotech
Dr Boreham’s Crucible: Transforming the cardiac ablation market takes ticker… and time
Health & Biotech
ASX health stocks developing tech to bridge labour gaps
Health & Biotech
Basement to Breakthrough: Imricor transforms heart treatment with MRI
News
Closing Bell: Miners lead ASX; Renu Energy spikes on hydrogen offer; WEB plunges over 30pc
Health & Biotech
Imricor eyes worldwide expansion with progress on US and EU regulatory approval
Health & Biotech
ASX medical disruptors pioneering new diagnostics and cutting-edge procedures
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but there’s ‘wind in the sails again’
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall in ‘lacklustre’ week
Health & Biotech
ScoPo’s Powerplays: ASX health stocks flat in ‘ocean with no breeze’
Health & Biotech
HealthInvest 2024 set to show off latest ASX healthcare innovators
News